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Stem cell therapies hold potential to stimulate tendon regeneration and homeostasis, which is maintained in response to the native
mechanical environment. Activins are members of the mechano-responsive TGF-β superfamily that participates in the regulation of several
downstream biological processes. Mechanosensitive membrane receptors such as activin can be activated in different types of stem cells via
magnetic nanoparticles (MNPs) through remote magnetic actuation resulting in cell differentiation. In this work, we target the Activin
receptor type IIA (ActRIIA) in human adipose stem cells (hASCs), using anti-ActRIIA functionalized MNPs, externally activated through a
oscillating magnetic bioreactor. Upon activation, the phosphorylation of Smad2/3 is induced allowing translocation of the complex to the
nucleus, regulating tenogenic transcriptional responses. Our study demonstrates the potential remote activation of MNPs tagged hASCs to
trigger the Activin receptor leading to tenogenic differentiation. These results may provide insights toward tendon regeneration therapies.
© 2018 Elsevier Inc. All rights reserved.
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Figure 1. Schematic representation of cellular Activin A receptor targeting with MNPs functionalized with Anti-Activin type IIA antibody (MNPs-ActRIIA) for
tenogenic differentiation.
1150 A.I. Gonçalves et al / Nanomedicine: Nanotechnology, Biology, and Medicine 14 (2018) 1149–1159are involved in mature tendon repair are not well established,
hampering the development of successful cell based therapies
toward tendon regeneration.
Signaling cascades are the main routes of communication
between themembrane and intracellular regulatory targets. Among
them, TGF-β/Smad2/3 was reported as one of the most relevant
pathway involved in tenogenic differentiation.3,4 The transforming
growth factor-β (TGF-β) superfamily comprises of the TGFβs,
activins, NODAL, bone morphogenetic proteins (BMPs), growth
and differentiation factors (GDFs) and anti-Müllerian hormone
(AMH).5 Both TGF-β and mechanical stimulation were found to
activate the Smad2 and Smad3 molecules, downstream mediators
of TGF-β type I (activin receptor-like kinases, ALKs) and type II
receptors, suggesting stress-activated TGF-β signaling drives
tenogenesis.6,7 ActivinβA has been suggested to activate SMADs
pathway8,9 and to be involved in the regulatory pathway of
tenomodulin,10 a type II transmembrane glycoprotein suggested as
tendon specific marker.11,12
Since tendons are notably sensitive to mechanical forces, the
use of magnetic mechano-activation might constitute an effective
approach to commit stem cells towards the tenogenic lineage
through mechanosensing signaling cascades such as TGF-β/
Smad2/3 pathway. The technology of remote activation of
mechanotransduction via magnetic nanoparticles (MNPs) has
been successfully employed using the MICA Bioreactor (MICA
Biosystems Ltd) to deliver the magnetic field to MNPs-tagged
cells in both 2D and 3D environments.13,14 MNPs-tagged cells
renders magnetic responsiveness to the engineered systems with
potential to be remotely controlled and tuned by the actuation of
an external magnetic field stimulating cells in vitro and upon
implantation.15 Additionally, the magnetic field was shown to
impact biological processes16,17 and to render a positive outcome
in tissue healing.18,19 Thus, in this study we propose toinvestigate a magnetically actuated TE approach using an
externally applied oscillating magnetic field over stem cells
tenogenic phenotype commitment (Figure 1). Human
adipose-derived stem cells (hASCs) were labelled with MNPs
previously functionalized with anti-Activin receptor type IIA
antibody. The magnetic actuation is expected to directly activate
the mechanosensitive membrane receptor via functionalized
MNPs, stimulating hASCs towards controlled cellular responses,
more specifically regulating the transcription of tenogenic
associated genes and driving differentiation. In this way, we
can compare specific MNPs tagging with nonspecific effects of
an oscilating magnetic field at the cell level.
Previous works using biofunctionalized MNPs targeted to the
mechano-responsive ion channel TREK1,Wnt Frizzled or PDGFRα
and β receptors, have shown the promotion of an osteogenic, or
smooth muscle cell phenotype, respectively, in hMSCs in vitro and
in vivo demonstrating the potential for translation as an enabling
approach for cell therapies.13,14,20,21 This raised the hypothesis that
this approach can be extended to other tissues of themusculoskeletal
system, such as tendons, where stem cell therapies have already been
shown to be effective as veterinary treatments and would benefit
from further control of differentiation.22 In this study, we have
identified the cell surface receptors which are likely to be
mechano-magnetically targeted and investigated if we can activate
cell signalling pathways downstream.Methods
Magnetic nanoparticles (MNPs) conjugation with antibody
Carboxyl functionalized magnetic nanoparticles (nano-
mag®-D, 09-02-252, Micromod) were covalently coated with
Anti-Activin Receptor type IIA (ActRIIA) antibody (ab135634)
Table 1
Primers used for quantitative RT-PCR analysis.
Gene Sequence NCBI reference
Human Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) F- GGGAGCCAAAAGGGTCATCA
R- GCATGGACTGTGGTCATGAGT
NM_001256799.1
Collagen, Type I, alpha 1 (COL1A1) F- CCCCAGCCACAAAGAGTCTAC
R- TTGGTGGGATGTCTTCGTCT
NM_000088.3
Collagen, Type III, alpha 1 (COL3A1) F- CCTGAAGCTGATGGGGTCAA
R- CAGTGTGTTTCGTGCAACCAT
NM_000090.3
Tenascin C (TNC) F- ACTGCCAAGTTCACAACAGACC
R- CCCACAATGACTTCCTTGACTG
NM_002160.3
Scleraxis (SCXA) F- AGAACACCCAGCCCAAACAGAT
R- TCGCGGTCCTTGCTCAACTTT
NM_001080514.2
Decorin (DCN) F- CTAGTCACAGAGCAGCACCTAC
R- CCAGGGAACCTTTTAATCCGGGAA
NM_001920.4
Tenomodulin (TNMD) F- CCGCGTCTGTGAACCTTTAC
R- CACCCACCAGTTACAAGGCA
NM_022144.2
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antibody (ab97196), “MNPs-IgG“, by carbodiimide activation as
described previously.14 Briefly, particles were activated using
EDAC (03449, Sigma) and NHS (130672, Sigma) dissolved in
0.5 M MES buffer pH6.3 (Sigma) for 1 h at room temperature
under continuous mixing. The particle suspension was washed
and re-suspended in 0.1 M MES buffer containing 60 μg of
anti-rabbit secondary antibody (ab97196). The particle suspen-
sion was continuously mixed overnight at 4 °C and then washed
and re-suspended in 0.1 mL MES buffer containing 10 μg of
Anti-Activin Receptor type IIA antibody. Particle suspensions
were mixed for 3h at room temperature and then blocked with
25mM Glycine (Sigma) for 30 minutes before final washing and
re-suspension in distilled water. Functionalized nanoparticles
were then analyzed for surface charge and size using a Zetasizer
3000 HSa (Malvern Instruments). Particles were diluted in dH20
and measurements performed at 25 °C. The size and surface
charge of ActRIIA-coated nanoparticles was compared to
IgG-coated nanoparticles.Cell isolation and expansion
Human adipose-derived stem cells (hASCs) were obtained
from lipoaspirate samples from the abdominal region and
isolated from surplus tissue samples, under protocols previously
established with Hospital da Prelada (Porto, Portugal) and with
informed consent of the patients. The content of the written
informed consent and related procedures were reviewed and
approved by the Hospital Ethics Committee.
Human ASCs were isolated from tissue samples and cultured
as described before,23,24 and have been previously characterized
by RT-PCR for CD44, STRO-1, CD105 and CD90 markers.23
Briefly, the tissue was rinsed in phosphate buffered saline (PBS,
Sigma-Aldrich) containing 10% of an A/A solution. The fat
solution was immersed in a 0.05% collagenase type II (Sigma/
C6885) solution for 45 min at 37 °C under mild agitation. The
digested tissue was centrifuged at 800 g for 10 min at 4 °C, after
which the supernatant was eliminated. Cells were expanded in
basal medium composed of αMEM (BE12-169F, Lonza)supplemented with 10% FBS (10270, Gibco) and 1% A/A
solution (DE17-603E, Lonza).
Phosphorylation assays
hASCs were seeded at a density of 100,000 cells/well in
tissue-culture 6-well plates (Falcon) and incubated with carboxyl
functionalized MNPs previously coated with anti-ActRIIA
antibody or with anti-Rabbit-IgG antibody, at 25 μg MNPs/
2×105 cells. After a 30 min labelling period, in basal serum-free
medium, with conjugated MNPs, hASCs were incubated/
stimulated for 2, 10, or 30 min in basal αMEM medium under
magnetic stimulated conditions (magnetic field of ≥25 mT from
an array of permanent magnets (NdFeB) situated beneath the
culture plates at a frequency of 1 Hz) with a vertical oscillating
magnetic bioreactor (MICA Biosystems Ltd) and non-stimulated
cells kept in identical conditions in incubator. hASCs cultured
without MNPs in αMEM medium supplemented with Recom-
binant Human/Mouse/Rat Activin A Protein (338-AC-010, R&D
systems) or TGF-β3 at 10 and 20 ng/mL25 were considered
positive controls of ActRIIA activation. The dose of ligands was
chosen based on literature and according to the phospho-Smad2/
Smad3 ELISA kit. The MNPs conjugated only with secondary
IgG antibody constitute the negative control of the ActIIRA
activation. After each incubation period, cells were analyzed by
enzyme-linked immunosorbent assay (ELISA) that recognizes
endogenous levels of phospho-Smad2 (Ser465/467) and
phospho-Smad3 (Ser423/425) proteins (PathScan®
Phospho-Smad2 (Ser465/467)/Smad3 (Ser423/425) Sandwich
ELISA, 12001, Cell Signaling Technology), following the
manufacturer’s instructions.
hASCs culture
hASCs were seeded at 10,000 cells/well in 24-well plates and
cultured in the following conditions for up to 14 days: i) αMEM
medium in static conditions (“ST“), ii) αMEM medium in
magnetically stimulated conditions (“MICA“), iii) αMEM
medium supplemented with Activin A (20 ng/mL) in ST, iv)
αMEM medium supplemented with Activin A (20 ng/mL) in
Figure 2. Phosphorylation assessment of Smad2/Smad3 in hASCs triggered by TGF-β-like ligands. (A) Schematic of the experimental design for the
phosphorylation assay. Treatment of hASCs with Activin A and TGF-β3 ligands for up to 60min and subsequent phospho-Smad2/Smad3 (pSmad2/3) detection.
(B) Assessment of pSmad2/3 by ELISA kit assay, in hASCs cultured in αMEM medium (cells untreated) or cultured in αMEM medium suplemented with
Activin A or TGF-β3 at 10 and 20 ng/mL for 10, 30 and 60min. Values represent the mean ± SD. Symbol *, **, *** and **** denotes study groups with
statistical significant difference P b 0.05, P b 0.01, P b 0.001 and P b 0.0001, respectively.
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or vi) αMEMmedium in the presence of MNPs-ActRIIA inMICA.
Medium was changed every 3 days. Tenogenic commitment of
hASCswas evaluated based on the deposition of tendon extracellular
matrix (ECM) related proteins and on real time RT-PCR analysis for
tendon-related markers as described in detail below.
Magnetically stimulated groups were placed in a commer-
cially available vertical oscillating magnetic bioreactor (MICA
Biosystems Ltd), providing a magnetic field of ≥25 mT from an
array of permanent magnets (NdFeB) situated beneath the
culture plates at a frequency of 1 Hz, provided every other day
for 1h sessions. Non-stimulated groups were kept in identical
conditions but without magnetic field.
Dextran immunolabelling
Fixed cells labeled with MNPs-ActRIIA or MNPs-IgG
undergoing dextran immunolabelling were permeabilized with
0.025% Triton-X100 (Sigma/X100)/PBS solution, blocked with
2% BSA (A9418, Sigma) in PBS (21-040-CVR, Corning) for 1 h
at room temperature and incubated overnight with mouse
monoclonal anti-Dextran antibody (60026FI.1, Stem Cell
technologies) in 0.1% BSA in PBS at 4 °C. Cells were rinsed
in PBS, following incubation for 1 h at room temperature with
anti-mouse IgG FITC antibody (F2012, Sigma). Samples were
stained with 4,6-Diamidino-2-phenyindole dilactate (DAPI,
40009, VWR) for 10 min and Phalloidin Tetramethylrhodamine
B isothiocyanate (P1951, Sigma) for 20 min. The images were
acquired under a Fluorescence Inverted Microscope (Axio
Observer, Zeiss).mRNA Extraction and quantitative polymerase chain reaction
Total RNA was extracted using TRI reagent (T9424, Sigma)
according to the manufacturer’s instructions. Briefly, 800 μL of
TRI reagent was added to each sample and stored at -80 oC. After
defrosting, samples were incubated with 160 μL of chloroform
(Sigma) for 15 min and 12,000 g centrifuged for 15 min at 4 oC.
The aqueous fraction was collected and an equal part of
isopropanol (Sigma Aldrich) was added. After 10 min, samples
were centrifuged at 12,000 g for 10 min at 4 °C. RNA pellet was
washed with 800 μL of 70% ethanol and subsequently
centrifuged at 7,500 g for 5 min at 4 °C. Air-dried RNA samples
were resuspended in 15 μL of RNase/DNase free water (Gibco).
RNA quantity and purity were determined with a NanoDrop
ND-1000 spectrophotometer (NanoDrop Technologies). The
cDNA synthesis was performed with the qScript cDNA
Synthesis kit (Quanta Biosciences) and using the Mastercycler
Realplex (Eppendorf) using an initial amount of total RNA of
1μg in a total volume of 20 μL. The quantification of the
transcripts was carried out by quantitative polymerase chain
reaction (qPCR) using the PerfeCTA SYBR Green FastMix kit
(Quanta Biosciences) following the manufacturer's protocol, in a
Real-Time Mastercycler Realplex thermocycler (Eppendorf).
The primers were pre-designed with PerlPrimer v1.1.21 software
(Table 1) and synthesized by MWG Biotech. GAPDH
(glyceraldehyde-3-phosphate dehydrogenase) was used as the
housekeeping gene. The 2-ΔΔCt method was selected to evaluate
the relative expression level for each target gene.26 All values
were first normalized against GAPDH values, and then to the
hASCs cells collected at day 0.
Figure 3. Development and characterization of functionalized MNPs complexes. A) Schematic representation of MNPs functionalization with anti-activin
receptor type IIA antibody by carbodiimide activation; B) Size and zeta potential analysis of MNPs functionalized with anti-activin receptor type IIA antibody
(MNPs-ActRIIA) or with IgG secondary antibody (MNPs-IgG).
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The amount of collagen and non-collagenous proteins
expressed by hASCs cultured in 2D was determined using a
semi-quantitative assay, namely Sirius Red/Fast Green Collagen
Staining Kit (9046, Chondrex). After cells fixation, the dye
solution was added and incubated for 30 min in order to
completely immerse the samples. A dye extraction buffer was
then mixed and the OD values read in a spectrophotometer
(Synergy HT, Biotek Instruments) at 540 nm and 605 nm.
Immunofluorescence
Cells were rinsed in PBS and fixed in formalin (INOPAT) prior
to the detection of Tenomodulin (sc-49324) and Fibromodulin
(ab81443) deposition. After cell permeabilization with 0.025%
Triton-X100 (Sigma/X100)/PBS solution, the blocking step was
performed using RTU Normal Horse Serum (RTU Vectastain Kit,
PK-7200, Vector). Then, cells were incubated overnight with
anti-tenomodulin and anti-fibromodulin antibodies, diluted in
antibody diluent with background reducing components from
Dako (S3022, Dako) at 4 °C. Samples were then rinsed in 0.025%
Triton-X100 (Sigma/X100)/PBS solution followed by incubation
for 1h at room temperature with the respective Alexa fluor 488
(Alfagene) considering the host species of the primary antibodies.
Samples were stained with 4,6-Diamidino-2-phenyindole, dilac-
tate (DAPI, 5 μg/μL, D9564, Sigma) for 10 min and with
Phalloidin–Tetramethylrhodamine B isothiocyanate (P1951,
Sigma) for 20 min. Samples were observed with a Fluorescence
Inverted Microscope (Axio Observer, Zeiss).
Statistics
Quantitative results are expressed as the mean ± standard
deviation. Two-way ANOVA followed by Bonferroni’s Multiple
Comparison test was assessed to determine whether differencesbetween sample groups were significant, unless specified.
Differences were considered significant when the P value was
b 0.05.Results
Assessment of Smad2/Smad3 phosphorylation in hASCs
triggered by TGF-β-like ligands
TGF-β-like ligands, Activin A and TGF-β3 known for their
functions in tendon development,10,27 were investigated as
inducers of serine/threonine receptor‘s activation and consequent
phosphorylation of Smad2/3 (Figure 2, A). Using two different
ligand doses (10 and 20 ng/mL) and at varying temporal
exposures, Smad2/3 signaling and subsequent gene expression
has been assessed. Moreover, Activin A and TGF-β3
ligand-receptor binding will serve as a positive experimental
control of the activation of ActRIIA receptor mediated by
MNPs-antibody complexes. We investigated the levels of
pSmad2/3 following 2, 10, 30 and 60 min of treatment.The
detection of pSmad2/3 proteins was rapid (at 10 min) and more
intense in Activin A supplemented medium at 20 ng/mL than in
medium supplemented with TGF-β3 ligand (Figure 2, B).
Development and characterization of functionalized MNPs
complexes
After antibody functionalization by carbodiimide activation
(Figure 3, A), the size and surface charge of MNPs-ActRIIA and
MNPs-IgG were characterized. The particle size increased after
IgG coating of MNPs in comparison to MNPs coated with
anti-ActRIIA (MNPs-ActRIIA). Conversely, the surface charge
increased in MNPs-ActRIIA (Figure 3, B).
In order to co-localize functionalized MNPs within hASCs,
MNPs-ActRIIA or MNPs-IgG labelled cells were visualized by
Figure 4. Dextran (green) immunofluorescence images ofA) hASCs labelled with MNPs-ActRIIA or MNPs-IgG. Cell nuclei are shown by DAPI (blue) and the
cytoskeleton by phalloidin (red); B) lower magnification images.
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dextran shell with an anti-dextran antibody (Figure 4),
suggesting that 30 min after labelling, there is a clear association
of MNPs-ActRIIA and MNPs-IgG with cells.
Triggering Smad2/Smad3 phosphorylation in hASCs by MNPs
complexes
The activin receptor activation was indirectly assessed
through detection of downstream phosphorylation of Smad2/3
using an ELISA kit assay that recognizes endogenous levels of
these proteins. Magneto-mechanical stimulated groups showed
significantly higher phosphorylation levels in relation to
non-stimulated and to Activin A control groups after 2 and 10
min, decreasing after 30 min (Figure 5, A) in MNPs-ActRIIA ST
and MNPs-ActRIIA MICA conditions. The detection of
phospho-Smad2/3 proteins seems to be more intense after
10min in hASCs labeled with MNPs-ActRIIA under magnetic
stimulation, which highlights a more efficient ActRIIA activa-
tion. Results also show a significant elevation of absorbance
values in comparison to the negative control group, MNPs-IgG,
or to the positive control group, Activin (Figure 5, B).
Triggering tenogenesis in hASCs using MNPs-ActRIIA complex
In this study, real time RT-PCR analysis, the production
assessment of collagen and non-collagenous proteins and the
deposition of Tenomodulin (TNMD) and Fibromodulin (FMOD)
tendon-related proteins were conducted up to 14 days uponActRIIA activation under magnetic field stimulation provided by
MICA bioreactor.
Gene expression analysis
The expression of tendon associated genes was found to be
higher in hASCs bound with MNPs-ActRIIA with and without
the magnetic stimulation after 7 days (Figure 6). PCR results
evidence higher gene expression values in MNPs-ActRIIA after
7 days under magnetic stimulation. Targeted mechano-activation
of the ActRIIA using magnetic actuation of MNPs attached to the
membrane receptor resulted in enhanced upregulation of
tenogenic genes, TNC, TNMD, SCXA, DCN, and COL3A1 but
not COL1A1. Interestingly, MNPs-ActRIIA binding alone
enhanced TNC expression but not other tenogenic genes, as for
example TNC gene expression is significantly higher in
MNPs-ActRIIA ST (P b 0.05) in comparison to Activin A ST
and to αMEM ST (P b 0.01).
Extracellular matrix formation assessment
Of the tendon dry weight, 60% is collagen type I arranged in
tensile-resistant fibers28 and other types such as collagen types
III (0-10%), IV (~2%), V, and VI. The non-collagenous matrix is
primarily made up of glycoproteins which include the proteo-
glycans such as decorin (DCN), tenascin C (TNC), fibromudulin
(FMOD) and tenomodulin (TNMD).29 ECM formation was
assessed by production of collagen and non-collagenous proteins
as depicted in Figure 7. Collagen and non-collagenous proteins
Figure 5. Phosphorylation assessment of Smad2/Smad3 in hASCs. A) Phospho-Smad2/Smad3 ELISA assay of hASCs cultured in Activin A (positive control)
and with MNPs-ActRIIA under static (ST) or under actuation of a vertically oscillating magnetic field (MICA) for 2, 10, and 30min; B) Phospho-Smad2/Smad3
ELISA assay of hASCs cultured with MNPs-ActRIIA or MNPs-IgG under static (ST) or under actuation of a vertically oscillating magnetic field (MICA) for up
to 10min; Values represent the mean ± SD. Symbol *, **, *** and **** denotes study groups with statistical significant difference P b 0.05, P b 0.01, P b 0.001
and P b 0.0001 respectively.
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from day 0 to 7 days and from 0 to 14 days, respectively
(statistical significant groups: a and b). Interestingly, the
collagen values obtained in MNPs-ActRIIA MICA condition
were significantly higher than in static conditions after 14 days.
These values were also higher than αMEM or Activin A
controls. The same trend was observed in non-collagenous
protein production.
Tendon specific markers assessment
FMOD is highly expressed in the tendon and identified as a
critical component of the tendon stem cell niche.30 The
immunodetection of TNMD and FMOD is presented in Figure 8,
A and B, respectively. Tendon-specific transcription factors such
as SCX3 are essential and involved in mechanoresponsive
tenogenesis through regulation of its downstream ECM proteins
such as the tendon marker TNMD31,32 and proteoglycans such as
FMOD. Tenomodulin and Fibromodulin proteins deposition was
increased by hASCs previously labeled with MNPs-ActRIIA in
comparison with hASCs cultured in basal αMEM or in αMEM
supplemented with Activin A (negative and positive controls,
respectively). Also, the detection of these proteins after 7 and 14
days of culture was higher when the oscillating magnetic field,
provided by MICA bioreactor, was applied.Discussion
Signal transduction molecules of the Smad family are
components of a critical intracellular pathway that transmit
signals mediated by transmembrane serine/threonine kinase type
II receptors into the nucleus. Smad2/3 signaling pathways areassociated with tendon development and transcriptional re-
sponses and, to date and to author’s knowledge, no published
studies have reported to locally target and activate Activin
receptors upon mechano-magnetic stimulation, in order to
modulate Smad2/3 signaling. Binding of TGF-β family ligands,
such as Activins or TGF-β3, to receptors, leads to the
recruitment, phosphorylation and activation of type I Activin
receptor (ALK4), which provides a binding site for the
downstream substrates, initiating the intracellular signaling
through activation of Smad proteins.33 In the present work, the
assessment of Smad2/Smad3 phosphorylation in hASCs trig-
gered by TGF-β-like ligands, showed increased absorbance
values in Activin A supplemented medium (20 ng/mL) after 10
min, what suggests a more effective phosphorylation of Smad
proteins. Therefore, Activin A at this concentration was selected
as the positive control for ActRIIA activation in the subsequent
experiments of this study. Indeed, the activation of the
ligand-receptor complex is described as a relatively fast step in
the TGF-β signal transduction, occurring within 2 min after
ligand stimulation, and the signal is relayed to the activation of
Smad proteins, which reach at maximal levels in up to 30-60
minutes.34
In order to remotely stimulate ActRIIA receptor in a
controlled way, MNPs complexes were developed and charac-
terized. The results of size and surface charge of the developed
complexes (MNPs-ActRIIA and MNPs-IgG) suggested im-
proved electrostatic interactions of the MNPs coated with
anti-ActRIIA with the negatively charged cell membrane,
which were further co-localized in hASCs after the 30 min
period of labelling by immunocytochemistry.
To understand the capability of functionalized MNPs
(MNPs-ActRIIA) to directly target and remotely activate the
Figure 6. Real time RT-PCR analysis of tenascin C (TNC), tenomodulin (TNMD), scleraxis (SCXA), decorin (DCN), collagen type I (COL1A1) and collagen
type III (COL3A1) gene expression of hASCs cultured for 7 days in αMEM medium, αMEM supplemented with Activin A (20 ng/mL) or labeled with
MNPs-ActRIIA in αMEM medium, under static (ST) or under actuation of a vertically oscillating magnetic field (MICA). Values represent the mean ± SD.
Symbol * and ** denotes study groups with statistical significant difference P b 0.05 and P b 0.01, P b 0.001, by one-way ANOVA.
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investigated the phosphorylation of Smad2/3 using MICA
bioreactor and comparing to static environment. The outcomes
suggested that ActRIIA is a mechanosensitive receptor that can
be remotely activated using Ab coated MNPs, whose action is
favored by the actuation of an external magnetic field provided
by MICA bioreactor. Previous works using biofunctionalized
MNPs targeted to mechano-responsive receptors demonstrated
an enhanced mechanoactivation of the targeted receptors caused
by movement of the MNPs-Ab complex in the magnetic field.-
14,21,35 Furthermore, the commitment of hASCs towards
tenogenesis using the MNPs-ActRIIA complex was studied.
Tenoblasts maturation to tenocytes is characterized by the
formation of enriched ECM and controlled by key tenogenic
transcription factors, such as SCX.36 The TGF-β signaling
pathway regulates a diverse group of cellular behaviors such as
proliferation, differentiation, and growth arrest37 and has also
been suggested as the most active pathway in tendon cells during
mouse limb development.38 Overall, magnetic actuation of
MNPs coated with ActRIIA bound to the receptor enhanced the
expression of all tendon related genes studied. Havis et al.
reported that blocking the TGF-β pathway with SB43 inhibitor,
significantly downregulated SCX and COL1a1, among othergene expression38 concluding that TGF-β is required via the
Smad2/3 intracellular pathway for expression of tendon-related
markers in mouse forelimbs.38 We can infer that MNPs-ActRIIA
and magnetic actuation synergistically influenced Smad2/3
mediators. This agrees with other studies using alternate
mechanical activation methods where phosphorylation assays,
and SCX and TNMD transcriptional activity was upregulated in
response to strain.12,31,39 Furthermore, the fluctuations in gene
expression from 7 to 14 days (Figure S1) may be related with
ligand depletion from the environment causing cells to lose the
stimulation and shut down the phosphorylation of Smad2, which
can occur within a few hours post stimulation.40,41 Dosage and
stimulation time of TGF-β-like ligands have effects on Smad
signaling and short-term ligand pulse stimulation results in
transient pSmad2, whereas serial pulses or continuous stimula-
tion results in sustained pSmad2.40 Moreover, there is a
time-delay for reaching the maximum pSmad2/3 phosphoryla-
tion, which we determined to be 10 min after treatment with
MNPs-ActRIIA or with Activin A supplementation at 20 ng/mL,
and nuclear accumulation and subsequent regulation of tran-
scriptional responses. Considering these two assertions and the
results of gene expression we can infer that as the complex
MNPs-ActRIIA was provided to hASCs once at the beggining of
Figure 7. Quantification of collagen and non-collagenous proteins by Sirius Red/Fast Green Collagen staining kit in hASCs labeled with MNPs-ActRIIA in
αMEMmedium, under static (ST) or under actuation of a vertically oscillating magnetic field (MICA). hASCs cultured for up to 14 days in αMEMmedium and
in αMEM supplemented with Activin A (20 ng/mL) were considered the negative and positive experimental controls, respectively. Values represent the mean ±
SD. Symbol *, **, *** and **** denotes study groups with statistical significant difference P b 0.05, P b 0.01, P b 0.001 and P b 0.0001 respectively; a and b
letters represent statistically different groups.
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time-dependent and transient mostly affecting gene expression
in early culture periods.
Additionally, the synthesis of a complex matrix of collagen
and non-collagenous proteins also supports the activation of
activin receptor by MNPs-ActRIIA complex under magnetic
actuation in a more efficient way than using the Activin A ligand
to trigger hASCs response. Considering the role of TNMD as
specific tendon marker and FMOD as a crucial proteoglycan
component of tendons that regulate physiological ECM
assembly, it was assessed the deposition of these markers by
hASCs tagged MNPs-ActRIIA. Tenomodulin has been sugested
to be expressed upon Activin II receptor stimulation by
myostatin, triggering the Smad2/3 signaling cascade and
increasing the expression of SCX that ultimately results in the
TNMD gene expression.10 Thus, upon MICA stimulation,
MNPs-ActRIIA complexes are likely to act over Activin II
receptor, activating the signaling cascade and ultimately
inducing the transcription of TNMD and its translation into
protein. Moreover, FMOD was suggested to play a role in the
formation of ECM and to regulate TGF-β levels.42 Also,
mutations in the small leucine-rich proteoglycan gene FMOD
result in irregularities in the diameter of collagen fibers in the
tendons.43 Herein, the higher deposition of TNMD and FMOD
together with Sirius Red/Fast Green Collagen staining assay and
RT-PCR, confirms the hypothesis of magnetically actuated
MNPs-tagged hASCs towards a tenogenic commitment. More-
over, it was clear in the present work that the induction of
Smad2/3 signaling elicited hASCs tenogenic response. However,
it is known that other variables outside the target cell determine
the extent of stimulation by TGF-β cytokines.44 Thus, futurestudies will take into account the impact of extracellular
regulators in Smad signaling dynamics, such as ligand exposure,
or the effect of antagonistic ligands.
Collectively, the present work has shown that the remote
activation of MNPs tagging mechanosensitive receptors of
hASCs may have potential for controlling stem cell differenti-
ation envisioning successful cell therapies for tendon regener-
ation. Previously, we have shown the potential benefit of this
apporach in orthopaedic bone tissue engineering and similar
strategies could be employed for tendon regeneration.13 It has
been demonstrated that magnetic MNPs tagging can be utilised
in tendon lineage comitment via ActRIIA/Smad2/3 signaling
cascade, as shown by phosphorylation of Smad2/3 proteins in
MNPs-ActRIIA tagged hASCs. Further investigation is required
to fully explore the mechanism behind signal activation and
downstream signaling events in response to MNPs-ActRIIA
stimulation and the effects on hASCs fate and differentiation.
The development of this technology raises the possibility of
remotely controlling TGF-β/Smad2/3 signaling and consequent-
ly the control of stem cell behavior. Overall, the remote
activation of MNPs tagged hASCs may have potential for
controlling stem cell differentiation following cell therapy and
modulation of signaling pathways involved in tendon
regeneration.Appendix A. Supplementary data
Supplementary data to this article can be found online at
https://doi.org/10.1016/j.nano.2018.02.008.
Figure 8. Immunocytochemistry of A) Tenomodulin and of B) Fibromodulin proteins (green) deposited by hASCs labeled with MNPs-ActRIIA in αMEM
medium, under static (ST) or under actuation of a vertically oscillating magnetic field (MICA). hASCs cultured for up to 14 days in αMEM medium and in
αMEM supplemented with Activin A (20 ng/mL) were considered the negative and positive experimental controls, respectively. DAPI (blue) stains cell nuclei.
Insets represent hASCs labeled with MNPs-ActRIIA in αMEM medium at day 0.
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